Spiros D. Garbis
Chief Executive Officer at Proteas Bioanalytics, Inc.
Spiros D. Garbis active positions
| Companies | Position | Start | End |
|---|---|---|---|
Proteas Bioanalytics, Inc.
 Proteas Bioanalytics, Inc. Internet Software/ServicesTechnology Services Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation. | Director/Board Member | - | - |
| Chief Executive Officer | - | - | |
| Chief Tech/Sci/R&D Officer | - | - | |
| Founder | - | - | |
| President | - | - |
Career history of Spiros D. Garbis
Statistics
International
| United States | 2 |
Operational
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Proteas Bioanalytics, Inc.
Proteas Bioanalytics, Inc. Internet Software/ServicesTechnology Services Proteas Bioanalytics, Inc. is an innovative proteomics platform that advances molecular biology, biomarker development, and precision medicine. The private company is based in Torrance, CA and was founded by Spiros D. Garbis and Antigoni Manousopoulou. The company provides proteomics services and solutions to unmet needs in the field of neurodegenerative disorders, coronary artery disease, and cancer. Proteas Bioanalytics has collaborated with thought leaders and innovators in the medical field to develop novel blood biomarkers that are predictive of the progression from pre-malignant to active myeloma. Spiros D. Garbis has been the CEO since incorporation. | Technology Services |
- Stock Market
- Insiders
- Spiros D. Garbis
- Experience
